GlassScriptPhysician profile
Lewis M Wiggins
NPI 1700174828
$7,717.00
in general payments reported to CMS, 2019-2025
38 companies · $1,852 in 2025
The $1,852 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,238 · 2020: $574 · 2021: $612 · 2022: $751 · 2023: $1,307 · 2024: $1,384 · 2025: $1,852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,542.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,011.10 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $835.01 | 2019-2025 | |
| Abbvie INC. | $748.67 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $714.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $515.96 | 2019-2025 | Xifaxan |
| Amgen INC. | $357.20 | 2019-2025 | Prolia, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $328.06 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $313.37 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Glaxosmithkline, LLC. | $252.15 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $215.68 | 2023-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $185.57 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $183.76 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $101.44 | 2021-2023 | Trintellix |
| Tela Bio, INC. | $90.02 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Bayer Healthcare Pharmaceuticals INC. | $85.49 | 2021-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lewis Wiggins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.